

I'm not a bot





Pfizer Celebrates 175 Years of Innovation, Outlines Successes and Future Plans for 2025 1. Our financial performance is presented excluding the impact of foreign exchange rates to provide a clearer view of our business trends. 2. The introduction of Royalty revenues as a separate line item in our consolidated statements of operations provides more detailed insights into our revenue streams. 3. ELIQUIS reflects alliance revenues and product revenues, while PREVJAR Family includes Prevnar 20/Apexxar and Prevnar 13/Prevenar 13 pediatric and adult products. 4. VYNDAQEL Family comprises global revenues from VYNDAQEL and VYNDAMAX in the U.S. and Japan, respectively. 5. COMIRNATY encompasses various COVID-19 vaccine formulas, including original monovalent, bivalent, and new formulations. 6. XTANDI primarily reflects alliance revenues and royalty revenues, with a recent reclassification of royalty income into a separate line item within Total revenues. 7. Reported net income and diluted EPS are calculated according to U.S. GAAP, while adjusted income and EPS take into account certain adjustments for amortization, acquisition-related items, discontinued operations, and significant items. Pfizer uses alternative financial measures, which are reconciled to standard US accounting practices. The company's recent developments include the FDA approval of Hympavzi (marstacimab-hncq) for treating adults and adolescents with hemophilia A or B without inhibitors. Additionally, Pfizer has partnered with the American Cancer Society on a \$15 million initiative to address cancer care disparities. Information about Zipline and Accord for a Healthier World can be found on Pfizer's website. The company has also supplied over one billion doses of pneumococcal conjugated vaccine to lower-income countries through Gavi, the Vaccine Alliance. This annual review covers Pfizer's global operations from January 1 to December 31, 2024, and discusses key aspects of its purpose, strategy, and performance. It includes forward-looking statements regarding the company's future plans, including product development, commercialization, and investments in digital technology and AI. However, these projections are subject to various risks and uncertainties that may impact their realization. actual results could differ significantly from past results, future plans and projections due to various factors. For a comprehensive list of potential risks and uncertainties, please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2024, as well as its subsequent reports on Forms 10-Q and 8-K. These documents can be found on our website (www.pfizer.com) and the U.S. Securities and Exchange Commission's (SEC) website (www.sec.gov). The forward-looking statements in this report are based on data available up to December 31, 2024, unless otherwise stated. We do not undertake to update or revise these statements as new information becomes available or in response to future events or developments. All trademarks mentioned belong to their respective owners. Our common stock is primarily listed on the New York Stock Exchange, and also traded on various U.S. regional exchanges. For inquiries related to shareholder accounts and stock transfer matters, please contact our Stock Transfer Agent and Registrar, Computershare. We also provide information on services such as direct purchase of Pfizer stock, dividend reinvestment, and automatic monthly or bi-monthly investments through Computershare. Additionally, you can learn more about public policy at Pfizer on our website. Useful links include our investor relations page, contact information, privacy policy, careers, and general terms. For further information about Pfizer, please visit our website (www.pfizer.com) or follow us on social media platforms such as Facebook, Instagram, YouTube, LinkedIn, and X.com. We may use our website to disclose material information and comply with Regulation Fair Disclosure requirements. We communicate through various channels including conference calls, webcasts, social media like our Facebook page, Instagram account, YouTube channel, LinkedIn page, and X (previously known as Twitter) accounts. Information on our website or these mentioned platforms isn't automatically included in this 2024 Annual Review document. It's possible that this report may link to external websites managed by third parties, over which Pfizer has no control. These links are provided for convenience purposes only. We make no guarantees about the accuracy, timeliness, or completeness of information on such external sites. Using another website that links back to our 2024 Annual Review doesn't imply any partnership between Pfizer and that site's operator. Your use of any third-party platform will be governed by its own terms and policies (including privacy settings).

Pfizer annual report 2021. Pfizer annual report 2024 pdf. Pfizer india annual report 2024. Pfizer annual report. Pfizer jaarverslag. 2017 pfizer annual review. Pfizer limited annual report 2024.